AbiertoNCT07491497⚑ Reportar un problema con este anuncio

Estudio de fase 1/2 de TRI-611 en cáncer de pulmón no microcítico ALK-positivo

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

Abierto a todos los participantes calificados

Fase

PHASE1, PHASE2

Inscripción

160 (estimado)

Rango de edad

18 Years to —

Sexo

ALL

Resumen

The goal of this trial is to learn about the safety and recommended dose of TRI-611 in adults with ALK-positive non-small cell lung cancer (NSCLC), and to evaluate its antitumor activity. The study runs in two parts: a dose-finding part and an expansion part across three groups defined by prior therapy.

Mostrando el original en inglés

Afecciones estudiadas

ALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer

Patrocinadores

TRIANA Biomedicines, Inc.Principal

Ubicaciones del estudio

University of Colorado Cancer Center

Aurora, Colorado

Kyle Concannon, MD, PRINCIPAL_INVESTIGATOR

Washington University Medical Center

St Louis, Missouri

Saiama Waqar, MD, PRINCIPAL_INVESTIGATOR

Memorial Sloan-Kettering Cancer Center

New York, New York

Memorial Sloan Kettering Cancer Center, CONTACT

Taylor Cancer Research Center

Maumee, Ohio

Stephanie Ambrose, CONTACT

SCRI Oncology Partners

Nashville, Tennessee

AskSarah, CONTACT

START Mountain Region

West Valley City, Utah

Olivia Darais, CONTACT

NEXT Virginia

Fairfax, Virginia

Alexander Spira, MD, PRINCIPAL_INVESTIGATOR